JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00

Altimmune (NASDAQ:ALT - Get Free Report) had its price target dropped by research analysts at JMP Securities from $25.00 to $15.00 in a report released on Thursday,Benzinga reports. The firm currently has a "market outperform" rating on the stock. JMP Securities' price target suggests a potential upside of 247.62% from the company's previous close.

A number of other equities research analysts have also commented on the company. Wall Street Zen lowered Altimmune from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Friday, June 27th. Finally, William Blair restated a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Altimmune currently has a consensus rating of "Moderate Buy" and an average price target of $18.20.

Altimmune Trading Down 9.0%

Shares of NASDAQ ALT opened at $4.32 on Thursday. The company has a market capitalization of $349.98 million, a P/E ratio of -3.43 and a beta of 0.47. Altimmune has a 12 month low of $2.90 and a 12 month high of $11.16. The stock has a 50 day moving average of $5.67 and a 200-day moving average of $5.89.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. During the same quarter last year, the business earned ($0.34) earnings per share. Analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Trading of Altimmune

Several institutional investors have recently added to or reduced their stakes in ALT. Baader Bank Aktiengesellschaft bought a new stake in Altimmune during the second quarter worth about $133,000. Geneos Wealth Management Inc. bought a new position in Altimmune during the 1st quarter valued at approximately $50,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after acquiring an additional 2,241 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Altimmune by 5.4% during the 1st quarter. MetLife Investment Management LLC now owns 46,870 shares of the company's stock valued at $234,000 after acquiring an additional 2,396 shares during the period. Finally, AlphaQuest LLC bought a new position in Altimmune in the 1st quarter worth $99,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.